|
- Repare Therapeutics | Synthetic Lethality Precision Oncology
Repare Therapeutics is a clinical-stage precision oncology company enabled by its proprietary synthetic lethality approach to developing novel medicines
- Repare | Synthetic Lethality Precision Oncology | About
Repare Therapeutics is a leading clinical-stage precision oncology company enabled by our proprietary synthetic lethality approach to discovering and developing novel therapeutics We developed highly targeted cancer therapies focused on genomic instability, including DNA damage repair
- Repare Therapeutics | Precision Oncology | Investor Relations
Repare Therapeutics is a leading clinical-stage precision oncology company enabled by synthetic lethality approach to the discovery and development of novel therapeutics
- Repare | Synthetic Lethality Precision Oncology | Pipeline
Check out the drug pipeline for Repare Therapeutics, a clinical-stage precision oncology company discovering and developing synthetic lethal therapies
- Repare | Synthetic Lethal Therapies | Discovery Platform
Learn about scientifc discovery platorm at Repare Therapeutics, a clinical-stage precision oncology company developing novel, synthetic lethal medicines
- Repare Therapeutics | Synthetic Lethality | Press Releases
Press releases for Repare Therapeutics, a clinical-stage precision oncology company discovering and developing novel, synthetic lethal medicines
- Repare | Synthetic Lethality Precision Oncology | Leadership
Learn about the team at Repare Therapeutics, a clinical-stage precision oncology company discovering and developing novel, synthetic lethal medicines
- Repare Therapeutics | Synthetic Lethality | Polϴ Inhibitor
Repare is developing a small molecule inhibitor of polymerase theta, or Polθ, a SL target associated with BRCA mutations and other genomic alterations
|
|
|